Specipig, a CataloniaBio & HealthTechmember, closed 2021 achieving 150 preclinical research projects andreinforcing its position as the reference preclinical ContractResearch Organisation (CRO) for the globalpharmaceutical, biotechnology and medical technology industry.

The projects include efficacy, safety and tolerancestudies for new biomedical components, stem cell implants, dental implants,kidney transplants and the validation of latest-generation surgical robots like Bitrack, amongothers.

Jaume Amat, CEO ofSpecipig, notes that the company ended theyear positively for the third time in a row since itstarted in 2013, increasing 50% from last year: “We believe these results arevery positive because they show a consolidation of Specipig’s growth in linewith our goals and they mean we can continue investing in cutting-edge facilities andtalent.” 99% of the company’s revenue is international, with clients in more than 10 countries.

In 2022, Specipig will continue boosting its local andinternational presence. “Despite being a small CRO, our experience and specialisation are unique andhighly valued in the industry, as are our agility, flexibility and open doorsfor our customers,” explains Specipig Business Development Manager AsselaBosch.

Specipig has facilities near Barcelona airport, astrategic location to collaborate with international experts, and a team of 20 qualified professionals.

Photo: Specipig CEO Jaume Amat and Specipig BusinessDevelopment Manager Assela Bosch.